Glaukos Corporation (GKOS) Tops Q2 EPS by 10c; Raises Outlook

Glaukos Corporation (NYSE: GKOS) reported Q2 EPS of $0.06, $0.10 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $28.6 million versus the consensus estimate of $24.45 million.

“We are extremely pleased and excited about the way ophthalmic surgeons are embracing our flagship iStent® Trabecular Micro Bypass stent to effectively manage glaucoma patients’ intraocular pressure,” said Thomas Burns, president and chief executive officer of Glaukos. “Our second quarter results illustrate the continuing momentum of iStent’s adoption ramp, driven by our efforts to grow our customer base, expand the body of clinical evidence that demonstrates iStent’s reliable performance and extend our reach to key international markets.”

GUIDANCE:

Glaukos Corporation sees FY2016 revenue of $105-107 million, versus prior guidance of $100-102 million and the consensus of $101.1 million.

For earnings history and earnings-related data on Glaukos Corporation (GKOS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c